Compare WOLF & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | GLUE |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2025 | 2021 |
| Metric | WOLF | GLUE |
|---|---|---|
| Price | $24.87 | $9.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $24.00 | ★ $25.38 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | $123,672,000.00 |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | 19.00 | ★ 63.54 |
| 52 Week Low | $13.49 | $9.31 |
| 52 Week High | $80.82 | $25.77 |
| Indicator | WOLF | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 32.71 |
| Support Level | $23.31 | N/A |
| Resistance Level | $26.70 | $12.00 |
| Average True Range (ATR) | 2.31 | 0.60 |
| MACD | 0.49 | -0.05 |
| Stochastic Oscillator | 61.73 | 17.44 |
Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).